About Invion

Australian life-sciences firm Invion is leading the global clinical development of a novel PhotoDynamic Therapy (PDT) for cancer. Invion's novel photosensitiser (the agent used in PDT) is called PhotosoftTM. Invion's proprietary formulations of PhotosoftTM include an improved version called IVX-P02.

Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of the PhotosoftTM technology by licensor The Cho Group, which is based in Hong Kong. The Cho Group has funded and successfully commercialised a number of unique, advanced technologies.

Invion has an agreement with The Cho Group to conduct the clinical development of the PhotosoftTM technology globally. The Cho Group provides non-dilutive funding for the research into and clinical trials of PhotosoftTM via an R&D services agreement with Invion. The provision of non-dilutive funding is part of a global development strategy for PhotosoftTM.

Invion has an alliance with a leading Australian medical research institute, the Hudson Institute of Medical Research, to progress the PhotosoftTM research program.

Cancer expert Dr Andrew Stephens, the head of the Ovarian Cancer Biomarkers Research Group at the Hudson Institute, says the PhotosoftTM technology has many potential applications, particularly in cancer types that are already resistant to current chemotherapies.

In early 2019, Invion demerged its two respiratory assets – nadolol and zafirlukast - into a newly established Australian public unlisted company, Chronic Airway Therapeutics Ltd (CAT).

The demerger allows each company and management team to focus on the development of its respective assets.

Invion has been listed on the Australian Securities Exchange since 25 February 2011 under the ticker "IVX".